Table 3.
Clinical and management characteristics of alpelisib-related dAEs
| Any grade rash (%a) |
Grade 1/2 (%a ,%b) | Grade 3 (%a ,%c) | |
| Morphology (n=29) | |||
| Maculopapular | 26 (90) | 15 (52, 83) | 11 (38, 100) |
| Acneiform | 3 (10) | 3 (10, 17) | 0 (0, 0) |
| Symptoms (n=19) | |||
| Pruritic | 7 (36) | 2 (11, 25) | 5 (26, 46) |
| Burning | 6 (32) | 2 (11, 25) | 4 (21, 36) |
| Asymptomatic | 6 (32) | 4 (21, 50) | 2 (11, 18) |
| Management (n=41) | |||
| No treatment | 4 (10) | 4 (10, 18) | 0 (0, 0) |
| Topical corticosteroids | 2 (5) | 1 (2, 5) | 1 (2, 5) |
| Oral antihistamine | 4 (10) | 4 (10, 18) | 0 (0, 0) |
| Oral antihistamine | 13 (31) | 10 (24, 45) | 3 (8, 16) |
| Topical corticosteroids | |||
| Oral antihistamine | 4 (10) | 1 (2, 5) | 3 (8, 16) |
| Oral corticosteroids | |||
| Oral antihistamine | 14 (34) | 2 (5, 9) | 12 (29, 63) |
| Topical corticosteroids | |||
| Oral steroids |
a
Percentages derived from fraction reported subset of any grade rash (i.e. n=29 for rash morphology).
b
Percentages derived from fraction of reported subset within same grade rash (i.e. n=18 for grade 1/2 morphology).
c
Percentages derived from fraction of reported subset within same grade rash (i.e. n=11 for grade 3 morphology).